The Sodium–Volume Defence Hypothesis or Sodium–Struggle Hypothesis of Autism frames a substantial subset of autism not as the consequence of clinical hyponatraemia in the narrow laboratory sense but as a developmental imprint of recurrent movement toward low-effective sodium pressure along the sodium–volume survival axis. The core claim is that vertebrate physiology does not defend serum sodium as an isolated number. It defends a coupled survival geometry in which sodium-weighted support of extracellular tonicity, effective arterial volume, tissue perfusion, and cellular viability must remain coherent enough to prevent collapse. In this framework, “effective sodium” is shorthand for sodium’s functional contribution to extracellular stability, not a new laboratory analyte. Low-effective sodium therefore names a physiological state in which sodium’s contribution to tonicity, volume support, or perfusion-effective distribution becomes fragile, misweighted, or repeatedly threatened even when measured serum sodium remains within the reference range. Clinical hyponatraemia remains a real initiating route, but it is not the defining requirement. The defining requirement is repeated recruitment of defence systems before overt collapse occurs, followed by incomplete reset during fetal and early postnatal calibration windows. The hypothesis is thus about the history of rescue, not the chemistry panel captured at one moment. It is organised around a non-teleological principle of survival prioritisation. When physiology approaches a state in which extracellular stability, pressure, or perfusion may fail, the organism does not optimise for later developmental precision. It triages for immediate viability. AVP, RAAS, autonomic vasomotor recruitment, glucocorticoid support, renal sodium and water conservation, and cellular volume-preserving transport strategies are mobilised because death from perfusion failure is immediate, whereas long-horizon refinement of inhibitory timing and circuit pruning can be deferred. What is proposed to persist is not chronic dysnatraemia but developmental imprinting across endocrine, vascular, renal, autonomic, hypothalamic, glial, and ion-transport systems. This framing makes the Sodium Paradox central rather than peripheral. The Sodium Paradox is the possibility of normal or high osmolality with functional sodium insufficiency. Sodium can be functionally inadequate even when total osmolality is preserved or elevated because the relevant issue is not osmolality alone but which osmoles are carrying it, how water is distributed, whether the intravascular fraction is perfusion-effective, and whether regulatory systems read the state as coherent or unstable. A translocational or osmotic mismatch arises when glucose or other non-ionic osmoles raise osmolality and move water across compartments faster than sodium is re-equilibrated. A dilutional state can coexist with underfilling when water expansion does not translate into stable effective arterial volume. Endocrine mismatch can occur when fluid consequences are transmitted but peptide rescue is filtered or delayed. The result is a physiologically credible condition in which serum sodium may appear acceptable, osmolality may be normal or high, yet tissues and controllers still confront low-effective sodium. This is why the hypothesis insists on distinguishing clinical hyponatraemia from functional sodium insufficiency, and on distinguishing dilution from perfusion failure from translocational states rather than collapsing them into one category. The maternal side of the hypothesis begins with the observation that pregnancy is an exercise in defending coupled tonicity, volume, perfusion, and placental conductance under changing load. Maternal physiology may encounter dilution-prone inputs, glycaemic oscillations, vascular underfilling, placental resistance, inflammatory endothelial leak, altered oncotic balance, or pharmacologically induced antidiuresis. Low-TDS or other solute-poor water intake is treated cautiously but explicitly within this model as one plausible contributor to dilution-prone states, particularly when consumed in volume or when infant feeds are prepared with very low-solute water. The claim is not that low-TDS water is a universal cause, but that fluid which expands water more readily than ionic support can, under the right conditions, push the system toward true dilution. Gestational diabetes and repeated glucose excursions represent a distinct but convergent route. Here total osmolality may rise, yet the rise is carried in part by glucose rather than sodium, producing oscillatory osmotic stress and translocational water shifts that can yield functional low-effective sodium in the fetal readout. Highly bioavailable inorganic phosphate additives provide another modern route. By increasing phosphate load and contributing to hyperphosphataemia, FGF-23 signalling, phosphaturia, vascular stiffening, and nitric-oxide-limiting states, they can redistribute sodium handling across nephron segments, reduce proximal sodium reclamation, and add a downstream sodium-handling burden even without classic salt loss. Selected medication-related dilutional states enter the same geometry more briefly but importantly: SSRIs, thiazide-like states, oxytocin with hypotonic carriers, and other water-retentive conditions can create transient but developmentally relevant fluid–solute imbalance. These are not presented as equal in effect size or certainty. They are presented as convergent entry routes into the same control problem. The placenta is the decisive hinge because the fetus does not receive maternal physiology directly. The placenta transforms rather than replicates maternal signals. It is a transport epithelium, endocrine filter, peptide-metabolising barrier, vascular regulatory surface, and timing transformer. Water transfer is rapid and follows osmotic gradients...